{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:16:25Z","timestamp":1792163785583,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pnpbp.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T03:04:45Z","timestamp":1489460685000},"page":"101-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics"],"prefix":"10.1016","volume":"76","author":[{"given":"Michael","family":"Paulzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-4117","authenticated-orcid":false,"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Stegmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Gr\u00fcnder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen R.J.","family":"Schruers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Lammertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.03.002_bb0005","first-page":"625","article-title":"Forty years of antipsychotic drug research\u2013from haloperidol to paliperidone\u2013with Dr. Paul Janssen","volume":"57","author":"Awouters","year":"2007","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1055\/s-2007-1004590","article-title":"Increase of risperidone concentration under chlorprothixene comedication\u2013a case report","volume":"41","author":"Bader","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-2005-862617","article-title":"Determination of five commonly used antipsychotics in human serum by High Performance-Liquid Chromatography (HPLC) and electrochemical detection","volume":"38","author":"Bader","year":"2005","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0020","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00613523","article-title":"Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites","volume":"31","author":"Balant-Gorgia","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jpainsymman.2013.07.018","article-title":"Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development","volume":"48","author":"Bush","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/cap.2010.0038","article-title":"Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents","volume":"21","author":"Calarge","year":"2011","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/00007691-200502000-00019","article-title":"Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service","volume":"27","author":"Castberg","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0040","first-page":"439","article-title":"Neuroleptic malignant syndrome: case report and discussion","volume":"169","author":"Chandran","year":"2003","journal-title":"CMAJ"},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2017.03.002_bb0045","first-page":"S89","article-title":"Clinical review of risperidone","volume":"38","author":"Chouinard","year":"1993","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1472-684X-12-2","article-title":"Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review","volume":"12","author":"Dietz","year":"2013","journal-title":"BMC Palliat Care"},{"issue":"Suppl. 16","key":"10.1016\/j.pnpbp.2017.03.002_bb0055","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0060","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0065","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(02)00292-X","article-title":"Anxiety and substance use comorbidity among inpatients with schizophrenia","volume":"61","author":"Goodwin","year":"2003","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00007691-199302000-00003","article-title":"Citalopram: interaction studies with levomepromazine, imipramine, and lithium","volume":"15","author":"Gram","year":"1993","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2003-38084","article-title":"Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine","volume":"36","author":"Gr\u00f6zinger","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0085","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1055\/s-0031-1286285","article-title":"Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety","volume":"44","author":"Haen","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/JCP.0000000000000127","article-title":"Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction","volume":"34","author":"Hefner","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0095","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-015-1403-7","article-title":"Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey","volume":"122","author":"Hefner","year":"2015","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0100","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0105","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-3-642-25761-2_10","article-title":"Interactions and monitoring of antipsychotic drugs","author":"Hiemke","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.eurpsy.2004.07.001","article-title":"Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia","volume":"19","author":"Higashima","year":"2004","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0115","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use","first-page":"1996","article-title":"Harmonised tripartite guideline, validation of analytical procedures: test and methodology","author":"International Conference on Harmonization","year":"1996"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties","volume":"244","author":"Janssen","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0125","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.289.13.1652","article-title":"Drug-drug interactions among elderly patients hospitalized for drug toxicity","volume":"289","author":"Juurlink","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-006-0098-y","article-title":"Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone","volume":"62","author":"Kohnke","year":"2006","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0135","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/0378-4347(88)80113-0","article-title":"Gas chromatographic-mass spectrometric study of urinary metabolism of melperone","volume":"427","author":"Koppel","year":"1988","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0140","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1600-0447.1993.tb03391.x","article-title":"Levomepromazine receptor binding profile in human brain--implications for treatment-resistant schizophrenia","volume":"87","author":"Lal","year":"1993","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0145","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0150","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31818679c9","article-title":"Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy","volume":"30","author":"Mannheimer","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0155","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0165","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-244X-14-166","article-title":"Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia","volume":"14","author":"Naidu","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0170","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/0006-3223(85)90174-X","article-title":"Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers","volume":"20","author":"Nishikawa","year":"1985","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0175","first-page":"142","article-title":"Richtlinie der GTFCh zur Qualit\u00e4tssicherung bei forensisch-toxikologischen Untersuchungen","volume":"76","author":"Paul","year":"2009","journal-title":"Toxichem. Krimtech."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0180","series-title":"Comorbid Anxiety in Schizophrenia and Schizoaffective Disorder","author":"Podea","year":"2015"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081208","article-title":"Torsadogenic risk of antipsychotics: Combining adverse event reports with drug utilization data across Europe","volume":"8","author":"Raschi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0190","first-page":"4","article-title":"Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons","author":"Sahlberg","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0195","first-page":"142","article-title":"Reversible oral dyskinesia associated with quetiapine in an adolescent: a case-report","volume":"20","author":"Sarro","year":"2011","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0200","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/0269881114541013","article-title":"Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review","volume":"29","author":"Sim","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199706000-00003","article-title":"Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine","volume":"19","author":"Suzuki","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2174\/1872312811206040008","article-title":"A transcellular assay to assess the P-gp inhibition in early stage of drug development","volume":"6","author":"Taur","year":"2012","journal-title":"Drug Metab Lett."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0215","author":"US Food and Drug Administration"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0220","author":"US Food and Drug Administration"},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0225","article-title":"Management of patients with risk factors","author":"Waldfahrer","year":"2013","journal-title":"GMS Curr. Top Otorhinolaryngol. Head Neck Surg."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0230","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bcp.2014.05.005","article-title":"The cytochrome P450-catalyzed metabolism of levomepromazine: a phenothiazine neuroleptic with a wide spectrum of clinical application","volume":"90","author":"Wojcikowski","year":"2014","journal-title":"Biochem Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/0091270009347867","article-title":"Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety","volume":"50","author":"Xiang","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.03.002_bb0245","first-page":"1263","article-title":"Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes","volume":"29","author":"Yasui-Furukori","year":"2001","journal-title":"Drug Metab. Dispos."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616304699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584616304699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:50:41Z","timestamp":1750103441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584616304699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":49,"alternative-id":["S0278584616304699"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.03.002","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}